H. Lundbeck A/S, a global leader in pharmaceuticals focused on brain health, has announced the appointment of Dianne Hol as the new Executive Vice President (EVP) of People & Organization, effective from 1 April 2024. Dianne
Hol will be instrumental in spearheading the company’s people strategy, aligning it closely with Lundbeck’s ambitious growth objectives.
Dianne Hol’s appointment is a strategic move by Lundbeck to harness her extensive international experience in HR leadership to further develop the organization. She joins Lundbeck from AstraZeneca, where she served as Vice President of Global Human Resources, contributing significantly to different global business areas, including BioPharmaceuticals & Japan. Prior to her tenure at AstraZeneca, Dianne was the Global Head of Human Resources at Roche Diabetes Care. Her educational background includes a Bachelor of Arts in Human Resources Management from Hogeschool van Utrecht, Netherlands.
Charl van Zyl, President and CEO of Lundbeck, expressed enthusiasm for Dianne’s upcoming role, highlighting her proven track record in driving performance and fostering talent. “Dianne’s leadership will be pivotal in our journey towards becoming an even more dynamic and innovative company,” van Zyl remarked.
Dianne Hol shared her excitement about joining Lundbeck, emphasizing her commitment to enhancing the company’s mission to improve the lives of those living with brain disorders. “I am thrilled to contribute to Lundbeck’s people strategy, fostering a culture where innovation thrives and every individual can achieve their best,” said Hol.
As EVP of People & Organization, Dianne Hol will focus on developing high-performing HR teams that are essential for supporting Lundbeck’s strategic objectives. Her role will be crucial in driving Lundbeck’s people strategy, enhancing company and employee performance, and building a culture that supports innovation and excellence.
By integrating Dianne Hol’s expertise and vision, Lundbeck aims to bolster its position as a pioneer in the pharmaceutical industry, specifically in the realm of brain health. Her leadership in People & Organization is set to catalyze Lundbeck’s continued growth and success in developing treatments that significantly impact the lives of patients worldwide.
